Lilly offers up to $1.9B in new drug discovery deal with Abbisko

Building on a pact from 2022, Eli Lilly has signed a new discovery collaboration with Abbisko Therapeutics that could see it pay the Chinese biotech up to $1.9 billion. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure…

Source: Endpoints News